CollPlant Biotechnologies Ltd. (CLGN)

Market Cap	22.06M
Revenue (ttm)	2.47M
Net Income (ttm)	-13.87M
Shares Out	12.72M
EPS (ttm)	-1.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	143,579
Open	1.610
Previous Close	1.660
Day's Range	1.590 - 1.790
52-Week Range	1.310 - 5.450
Beta	0.68
Analysts	Strong Buy
Price Target	11.50 (+562.82%)
Earnings Date	Aug 19, 2025

About CLGN

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The company’s products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. It offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixF...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 57
• Stock Exchange: NASDAQ
• Ticker Symbol: CLGN
• Website: https://collplant.com

Financial Performance

In 2024, CollPlant Biotechnologies's revenue was $515,000, a decrease of -95.30% compared to the previous year's $10.96 million. Losses were -$16.61 million, 136.6% more than in 2023.

Analyst Summary

According to 2 analysts, the average rating for CLGN stock is "Strong Buy." The 12-month stock price target is $11.5, which is an increase of 562.82% from the latest price.

Price Target

$11.5

(562.82% upside)

Analyst Consensus: Strong Buy